• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Sorrento, Igdrasol acquire E.U. distribution rights to Cynviloq from Samyang

Sorrento, Igdrasol acquire E.U. distribution rights to Cynviloq from Samyang

May 15, 2013
CenterWatch Staff

Sorrento Therapeutics, a development-stage biopharmaceutical company, and Igdrasol, a developer of personalized paclitaxel, have acquired exclusive distribution rights from Samyang Biopharmaceuticals, a South Korean corporation, to Cynviloq (marketed as Genexol-PMR in South Korea) in the 27 countries of E.U.

Igdrasol had previously obtained the exclusive U.S. distribution rights to Cynviloq from Samyang, and with this agreement, Samyang again recognizes the ability of Igdrasol's management team to leverage its domain expertise in nanomedicine for the development and commercialization of Cynviloq. STI has the right to acquire Igdrasol pursuant to a previously-announced option agreement, entered into in March 2013.

Cynviloq is a next-generation, branded, micellar diblock copolymeric paclitaxel formulation currently approved and marketed in several countries, including South Korea for metastatic breast cancer (MBC), non-small cell lung cancer (NSCLC) and ovarian cancer. It has also completed phase II studies for potential advancement into registration trials in the U.S.

Preliminary data analysis from an ongoing MBC phase III trial in South Korea has indicated a significantly improved overall response rate (ORR) for Cynviloq as compared to a solvent-based paclitaxel, a generic version of Taxol. More comprehensive data analyses will be presented at future medical conferences.

"We look forward to potentially making this important drug, Cynviloq, available to cancer patients who would greatly benefit from it—initially as an alternative to Abraxane and potentially in the future as a treatment option for indications such as bladder and ovarian cancers," said Vuong Trieu, Ph.D., CEO of Igdrasol.

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing